Kanghong Pharma Gains CFDA Approval For China's First Innovative MAb

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

December 20, 2013 -- Chengdu Kanghong Pharmaceutical Group was granted CFDA approval for Compaq Sipp ophthalmic injection (conbercept), a novel treatment for wet age-related macular degeneration. The drug is the first innovative, China-developed monoclonal antibody to gain regulatory approval, a significant milestone. The company believes its drug offers significant advantages over existing western MAbs such as Roche/Genentech’s similar drug, which is marketed as Avastin and Lucentis, giving conbercept the potential to become a blockbuster. More details....

Help employers find you! Check out all the jobs and post your resume.

Back to news